Halozyme Therapeutics Inc was incorporated in November 2007. It is a biopharmaceutical company engaged in making molecules into medicines for patients in need. The Company's research aims at extracellular matrix, an area outside the cell that provides structural support in tissues and orchestrates many biological activities, including cell migration, signaling and survival. All its approved product and product candidates are based on rHuPH20, its patented recombinant human hyaluronidase enzyme. rHuPH20 temporarily breaks down hyaluronic acid "HA" - a naturally occurring substance that is a major component of the extracellular matrix in tissues throughout the body such as skin and cartilage, this temporary degradation creates an opportunistic window for the improved subcutaneous delivery of injectable biologics, such as monoclonal antibodies and other large therapeutic molecules, as well as small molecules and fluids. It refers to the application of rHuPH20 to facilitate the delivery of other drugs or fluids as Enhanze technology. rHuPH20 is also the active ingredient in its first commercially approved product, Hylenex recombinant. Additionally, the Company is expanding its scientific work in the extracellular matrix by developing other enzymes and agents that target its primary aspects, giving rise to new molecular entities that can be indicated in endocrinology, oncology and dermatology. It operates under one segment, which includes all activities related to the research, development and commercialization of human enzymes that either transiently modify tissue under the skin to facilitate the delivery of injected drugs and fluids or to alter abnormal tissue structures for clinical benefit. The Company's proprietary program is engages in the formulation of rHuPH20 with prandial "mealtime" insulins for the treatment of diabetes mellitus. Company's Enhanze technology is the platform for the delivery of proprietary small and large molecules. It has combined rHuPH20 with an analog insulin, e.g., insulin lispro (Humalog), or Lispro-PH20, insulin aspart (Novolog), or Aspart-PH20, and insulin glulisine (Apidra), or each such combination, Analog-PH20, to accelerate their action. HTI-501, a recombinant human proteinase known as cathepsin L, is a lysosomal proteinase that acts by degrading collagen and is its first conditionally-active biologic. Collagen is an abundant protein in the body, particularly in connective tissue, and is present in high amounts in the extracellular matrix in the form of collagen fibers. The Company has engaged third parties to manufacture bulk rHuPH20 and its product Hylenex recombinant. Its patent portfolio includes 20 issued patents in the U.S., 57 issued patents in Europe and other countries in the world and some pending patent applications. The Company has collaborations with F. Hoffmann-La Roche, Ltd. and Hoffmann-La Roche, Inc. "Roche", Pfizer Inc. "Pfizer", Baxter Healthcare Corporation "Baxter" and Intrexon Corporation "Intrexon" with two products approved for marketing in Europe, as well as others at different stages of development. The FDA and comparable regulatory agencies in foreign countries regulate extensively the manufacture and sale of the pharmaceutical products that it has developed or currently are developing.